Certara, Inc. $CERT Shares Purchased by Royce & Associates LP

Royce & Associates LP grew its position in Certara, Inc. (NASDAQ:CERT – Free Report) by 6.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,937,683 shares of the company’s stock after purchasing an additional 181,657 shares during the period. Royce & Associates LP owned approximately 1.93% of Certara worth $27,027,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of CERT. BlackRock Inc. bought a new stake in shares of Certara during the second quarter valued at approximately $123,259,000. Haveli Investment Management LLC acquired a new position in shares of Certara during the second quarter worth approximately $48,470,000. Jefferies Financial Group Inc. acquired a new position in shares of Certara during the second quarter worth approximately $46,446,000. Bank of America Corp DE acquired a new position in shares of Certara during the second quarter worth approximately $11,780,000. Finally, Tejara Capital Ltd bought a new position in Certara in the 2nd quarter worth approximately $8,467,000. Institutional investors own 73.96% of the company’s stock.

Certara Price Performance

CERT stock opened at $11.57 on Monday. Certara, Inc. has a 52 week low of $4.45 and a 52 week high of $12.61. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -27.55 and a beta of 1.30. The firm’s 50-day moving average is $9.70 and its two-hundred day moving average is $7.40. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.29.

Certara (NASDAQ:CERT – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. Certara had a negative net margin of 16.14% and a positive return on equity of 3.36%. The business had revenue of $94.90 million during the quarter, compared to analysts’ expectations of $92.01 million. During the same period last year, the firm posted $0.14 earnings per share. The business’s revenue was down 9.3% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. On average, analysts forecast that Certara, Inc. will post 0.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on CERT. UBS Group restated a “neutral” rating and issued a $13.00 target price on shares of Certara in a research report on Friday, November 6th. Weiss Ratings upgraded Certara from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, November 9th. TD Cowen boosted their price target on Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Jefferies Financial Group reissued a “hold” rating and issued a $12.00 price target on shares of Certara in a research note on Friday, November 6th. Finally, Barclays increased their price target on Certara from $9.00 to $12.00 and gave the stock an “equal weight” rating in a research note on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.92.

Read Our Latest Research Report on CERT

Certara Company Profile

(Free Report)

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company’s offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.

Further Reading

Institutional Ownership by Quarter for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.